Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.36 |
| ▸ | AHR | P35869 | 1/20 | 0.35 |
| ▸ | CASR | P41180 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | TDO2 | P48775 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27413717 | 1.00 | ADRB2 (0.43) | ADRB2ALDH1A1ABCB11AHRCASR | |
| SCHEMBL1747998 | 0.85 | ALDH1A1 (0.55) | ALDH1A1TAAR1SLC6A4 | |
| SCHEMBL14120676 | 0.85 | ALDH1A1 (0.55) | ALDH1A1TAAR1SLC6A4 | |
| SCHEMBL20920134 | 0.85 | ALDH1A1 (0.55) | ALDH1A1TAAR1SLC6A4 | |
| SCHEMBL2737289 | 0.83 | ALDH1A1 (0.42) | ALDH1A1ABCB11AHRCASR | |
| Hydrochloric Acid SCHEMBL7788895 | 0.83 | ALDH1A1 (0.52) | ALDH1A1TAAR1SLC6A4 | |
| Hydrochloric Acid SCHEMBL3703308 | 0.83 | ALDH1A1 (0.52) | ALDH1A1TAAR1SLC6A4 | |
| Hydrochloric Acid SCHEMBL14120623 | 0.83 | ALDH1A1 (0.52) | ALDH1A1TAAR1SLC6A4 | |
| SCHEMBL4832246 | 0.80 | ADRB2 (0.56) | ADRB2LMNATP53HTTIDO1 | |
| SCHEMBL1748450 | 0.80 | ADRB2 (0.56) | ADRB2LMNATP53HTTIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1856075-A1 | SUBSTITUTED ARYLAMINE COMPOUNDS AND THEIR USE AS 5-HT6 MODULATORS | Epix Delaware, Inc. (US) | 2007-11-21 | — | — | EP | disclosed |
| US-20060205737-A1 | Substituted arylamine compounds and methods of treatment | GALENEA CORPORATION | 2006-09-14 | — | — | US | disclosed |
| WO-2006081332-A1 | SUBSTITUTED ARYLAMINE COMPOUNDS AND THEIR USE AS 5-HT6 MODULATORS | EPIX DELAWARE, INC. (US) | 2006-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205737-A1 | Substituted arylamine compounds and methods of treatment | HTR6, HTR2A, HTR3B | ADRB2 38/4885ALDH1A1 1488/4885ABCB11 1332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.